Amarin Corporation plc
NASDAQ•AMRN
CEO: Mr. Aaron D. Berg
Sector: Healthcare
Industry: Biotechnology
Listing Date: 1993-04-01
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Contact Information
Iconic Offices, The Greenway, Block C Ardilaun Court St Stephens Green, Dublin, 112-114, Ireland
353-0-166-99020
Market Cap
$330.20M
P/E (TTM)
-171.2
17.5
Dividend Yield
--
52W High
$20.90
52W Low
$7.00
52W Range
Rank57Top 83.3%
2.4
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.4 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$19.44M+0.00%
4-Quarter Trend
EPS
-$0.00+0.00%
4-Quarter Trend
FCF
$8.55M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Net Loss Significantly Reduced Net loss narrowed to $38.8M in 2025 from $82.2M in 2024, showing substantial operational improvement.
Gross Margin Expansion Achieved Gross margin increased to $120.9M in 2025, up from $81.4M in 2024, driven by lower Cost of Goods Sold.
Licensing Revenue Increased Licensing and royalty revenue rose 29% to $30.9M, primarily due to recognition of the Recordati Licensing Agreement upfront payment.
Risk Factors
Heavy Product Revenue Dependence Business remains substantially dependent on VASCEPA sales, limiting financial flexibility if market developments are negative.
U.S. Generic Competition Intensifies Increasing generic versions of icosapent ethyl in the U.S. continue to materially affect VASCEPA net product revenue.
Ongoing Antitrust Litigation Exposure Company faces costly and lengthy antitrust litigation regarding API supply, potentially resulting in significant fines or injunctions.
Outlook
Restructuring Cost Savings Expected Global Restructuring Plan implemented in June 2025 expects to reduce operating costs by approximately $70M annually moving forward.
Focus on International Expansion Continue assessing partnership opportunities outside the U.S. and Recordati territory for VASCEPA commercialization growth.
Future Capital Requirements Assessed Additional capital may be required to fund planned VASCEPA promotion and potential international commercialization efforts.
Peer Comparison
Revenue (TTM)
$183.87M
$75.27M
$51.13M
Gross Margin (Latest Quarter)
57207.7%
119.2%
100.0%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| RAPT | $959.26M | -14.8 | -61.8% | 1.6% |
| DSGN | $569.07M | -8.2 | -32.7% | 0.3% |
| DBVT | $563.12M | -3.6 | -295.2% | 14.5% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-22.7%
Growth Under Pressure
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
50%
Cash Flow Needs Attention
Deep Research
Next earnings:Mar 11, 2026
EPS:-$1.27
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data